Macrogenics Inc MGNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MGNX is a good fit for your portfolio.
News
-
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
-
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
-
MacroGenics to Participate in Upcoming Investor Conferences
-
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
-
MacroGenics to Participate in Upcoming Investor Conference
Trading Information
- Previous Close Price
- $15.70
- Day Range
- $14.13–15.59
- 52-Week Range
- $4.29–21.88
- Bid/Ask
- $14.46 / $15.24
- Market Cap
- $898.99 Mil
- Volume/Avg
- 2,440 / 1.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 15.56
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 339
- Website
- https://www.macrogenics.com
Comparables
Valuation
|
Metric
|
MGNX
|
VRDN
|
CELC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.84 | 2.91 | 2.88 |
Price/Sales | 15.56 | 1,810.15 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
MGNX
VRDN
CELC
Financial Strength
|
Metric
|
MGNX
|
VRDN
|
CELC
|
|---|---|---|---|
Quick Ratio | 4.28 | 17.93 | 12.78 |
Current Ratio | 4.48 | 18.26 | 13.43 |
Interest Coverage | −12.11 | −137.76 | −12.43 |
Quick Ratio
MGNX
VRDN
CELC
Profitability
|
Metric
|
MGNX
|
VRDN
|
CELC
|
|---|---|---|---|
Return on Assets (Normalized) | −45.12% | −42.76% | −35.57% |
Return on Equity (Normalized) | −91.96% | −82.42% | −49.08% |
Return on Invested Capital (Normalized) | −79.56% | −50.70% | −39.21% |
Return on Assets
MGNX
VRDN
CELC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dbvnfrrgth | Hvdd | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hjcpbnswl | Lzsbrks | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pnhwdbktr | Fcyjvt | $97.8 Bil | |
MRNA
| Moderna Inc | Qhwthjl | Fyxf | $38.8 Bil | |
ARGX
| argenx SE ADR | Rwjcyfms | Zbz | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Kydktvb | Rpl | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ppzywhzy | Vxsxyn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dqxpmmxx | Pdwqws | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jxjkmxdqq | Mmcll | $12.5 Bil | |
INCY
| Incyte Corp | Zqmcfdwg | Sxgrxym | $11.5 Bil |